Compare Heron Therapeutics Inc (HRTX) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs J M Smucker Co — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while J M Smucker Co trades at $120.56 (market cap $12.76B). The key difference: J M Smucker Co is far larger — about 187.6× Heron Therapeutics Inc's market cap, and J M Smucker Co pays a 3.75% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and J M Smucker Co for 74 Days on average.
| HRTX | SJM | |
|---|---|---|
Market Cap | $68.01M | $12.76B |
Volume | 1,891,941 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $132.34 |
52-Week Low | $0.27 | $89.53 |
Typical Hold Time | 35 Days | 74 Days |
Enterprise Value | $174.75M | $19.61B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
SJM trades at $115.93, down 0.74% on the day, with a bearish technical signal. The company reported a net loss of $1.23 billion in 2025 despite revenue growth to $8.73 billion, though recent quarters have beaten EPS estimates. Analyst consensus is a Buy with a $137.29 price target, and a dividend of $1.12 is scheduled for September 2026.
The outlook is mixed: strong recent earnings beats and positive analyst sentiment suggest upside, but high P/E of 54.17 and volatile profitability pose risks. Key opportunities include raised FY2027 guidance and brand strength, while risks involve margin pressure and high debt levels impacting shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
